Thymic carcinoma: Current staging does not predict prognosis

被引:118
作者
Blumberg, D [1 ]
Burt, ME [1 ]
Bains, MS [1 ]
Downey, RJ [1 ]
Martini, N [1 ]
Rusch, V [1 ]
Ginsberg, RJ [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, New York, NY 10021 USA
关键词
D O I
10.1016/S0022-5223(98)70273-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Thymic carcinomas are currently staged by Masaoka classification, a staging system for thymomas. We retrospectively evaluated surgical patients with thymic carcinoma to determine prognostic factors and to evaluate the usefulness of Masaoka staging in this disease, Methods: Our computerized tumor registry yielded 118 patients with thymoma, Review of pathologic material revealed 43 cases of thymic carcinoma, Collection of data was by review of hospital and physician charts and telephone contact with patients. Analysis of prognostic factors was performed in patients undergoing complete resection by the method of Kaplan-Meier and Cox proportional hazards regression, Results: Between 1949 and 1993, 43 patients underwent surgery for thymic carcinoma, Overall survival was 65% at 5 years and 35% at 10 years, Overall recurrence was 65% at 5 years and 75% at 10 years, On univariate analysis, survival was not dependent on age, sex, tumor size, or Masaoka stage but was dependent on innominate vessel invasion, By multivariate analysis, survival was dependent only on innominate vessel invasion, Conclusions: Patients with thymic carcinoma have a high rate of recurrence, Tumor invasion of the innominate vessels is associated with a particularly poor prognosis, Although Masaoka staging is useful in staging patients with thymoma, it does not appear to predict outcome for patients with thymic carcinoma.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 22 条
  • [1] BERNATZ PE, 1961, J THORAC CARDIOV SUR, V42, P424
  • [2] THYMOMA - A MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING SURVIVAL
    BLUMBERG, D
    PORT, JL
    WEKSLER, B
    DELGADO, R
    ROSAI, J
    BAINS, MS
    GINSBERG, RJ
    MARTINI, N
    MCCORMACK, PM
    RUSCH, V
    BURT, ME
    [J]. ANNALS OF THORACIC SURGERY, 1995, 60 (04) : 908 - 914
  • [3] CARLSON RW, 1990, CANCER, V66, P2092, DOI 10.1002/1097-0142(19901115)66:10<2092::AID-CNCR2820661008>3.0.CO
  • [4] 2-1
  • [5] Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
    Giaccone, G
    Ardizzoni, A
    Kirkpatrick, A
    Clerico, M
    Sahmoud, T
    vanZandwijk, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 814 - 820
  • [6] THYMIC CARCINOMA - 10 YEARS EXPERIENCE IN 20 PATIENTS
    HSU, CP
    CHEN, CY
    CHEN, CL
    LIN, CT
    HSU, NY
    WANG, JH
    WANG, PY
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 107 (02) : 615 - 620
  • [7] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [8] KIRCHNER T, 1989, THYMUS, V14, P195
  • [9] THYMIC CARCINOMAS - HISTOPATHOLOGICAL VARIETIES AND IMMUNOHISTOCHEMICAL STUDY
    KUO, TT
    CHANG, JP
    LIN, FJ
    WU, WC
    CHANG, CH
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (01) : 24 - 34
  • [10] LATTES R, 1962, CANCER, V15, P1224, DOI 10.1002/1097-0142(196211/12)15:6<1224::AID-CNCR2820150621>3.0.CO